Hemorrhagic ocular complications associated with the use of systemic thrombolytic agents

被引:52
作者
Chorich, LJ
Derick, RJ
Chambers, RB
Cahill, KV
Quartetti, EJ
Fry, JA
Bush, CA
机构
[1] Ohio State Univ, Coll Med, Dept Ophthalmol, Columbus, OH 43210 USA
[2] Fox Valley Ophthalmol, St Charles, IL USA
[3] Ohio State Univ, Coll Med, Div Cardiol, Columbus, OH 43210 USA
关键词
D O I
10.1016/S0161-6420(98)93023-8
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: This study aimed to report th ree patients with hemorrhagic ocular and orbital complications associated with the use of systemic thrombolytic agents. Design: The study design was a retrospective small case series. Participants: Three eyes of three patients were studied. Intervention: Surgical procedures to reduce intraocular pressure or relieve optic nerve compression were performed. Main Outcome Measures: Visual acuity and intraocular pressure were measured. Results: Three patients received an intravenous thrombolytic agent on diagnosis of an acute myocardial infarction, One patient had a spontaneous suprachoroidal hemorrhage develop with secondary acute angle closure glaucoma shortly after receiving tissue plasminogen activator, Another patient had an orbital hemorrhage develop on receiving tissue plasminogen activator 4 days after an uncomplicated cataract extraction, The third patient experienced an orbital hemorrhage while receiving streptokinase 1 day after undergoing an external levator resection. Two patients suffered significant visual loss due to glaucoma or compressive optic neuropathy. Conclusions: The onset of eye pain or visual loss after the administration of a systemic thrombolytic agent should alert the physician to the possibility of an ocular or adnexal hemorrhage, Prompt diagnosis and treatment can improve the likelihood of a favorable visual outcome.
引用
收藏
页码:428 / 431
页数:4
相关论文
共 18 条
[1]   RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR FOR THE TREATMENT OF LOWER-EXTREMITY PERIPHERAL VASCULAR OCCLUSIVE DISEASE [J].
BERO, CJ ;
CARDELLA, JF ;
REDDY, K ;
FOX, PS ;
HEALY, DA ;
JAFFE, J ;
NICHOLAS, GG .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 1995, 6 (04) :571-577
[2]   CLINICAL RISKS OF THROMBOLYTIC THERAPY [J].
CALIFF, RM ;
FORTIN, DF ;
TENAGLIA, AN ;
SANE, DC .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (02) :A12-A20
[3]   BILATERAL VITREOUS HEMORRHAGES AS A CONSEQUENCE OF THROMBOLYTIC THERAPY SUCCESSFULLY TREATED WITH VITRECTOMY IN A PATIENT WITHOUT DIABETES [J].
GREKOS, ZG ;
SCHOCKEN, DD .
AMERICAN HEART JOURNAL, 1995, 130 (03) :611-612
[4]   A COMPARISON OF IMMEDIATE ANGIOPLASTY WITH THROMBOLYTIC THERAPY FOR ACUTE MYOCARDIAL-INFARCTION [J].
GRINES, CL ;
BROWNE, KF ;
MARCO, J ;
ROTHBAUM, D ;
STONE, GW ;
OKEEFE, J ;
OVERLIE, P ;
DONOHUE, B ;
CHELLIAH, N ;
TIMMIS, GC ;
VLIETSTRA, RE ;
STRZELECKI, M ;
PUCHROWICZOCHOCKI, S ;
ONEILL, WW .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (10) :673-679
[5]  
JAFFE GJ, 1990, OPHTHALMOLOGY, V97, P184
[6]   Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid [J].
Kamei, M ;
Tano, Y ;
Maeno, T ;
Ikuno, Y ;
Mitsuda, H ;
Yuasa, T .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 121 (03) :267-275
[7]   ACUTE PULMONARY-EMBOLISM TREATED WITH THROMBOLYTIC AGENTS - CURRENT STATUS OF TPA AND FUTURE IMPLICATIONS FOR EMERGENCY MEDICINE [J].
KESSLER, CM ;
DRUY, E ;
GOLDHABER, SZ .
ANNALS OF EMERGENCY MEDICINE, 1988, 17 (11) :1216-1220
[8]   Choroidal hemorrhage associated with systemic tissue plasminogen activator [J].
Khawly, JA ;
Ferrone, PJ ;
Holck, DEE .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1996, 121 (05) :577-578
[9]   INTRAOPERATIVE FIBRINOLYSIS OF SUBMACULAR HEMORRHAGE WITH TISSUE-PLASMINOGEN ACTIVATOR AND SURGICAL DRAINAGE [J].
LEWIS, H .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 118 (05) :559-568
[10]  
Lundy DC, 1996, OPHTHALMOLOGY, V103, P274